Skip to main content English


Lukas Kenner
Prof. Dr. Lukas Kenner

Department of Pathology
Position: Professor

ORCID: 0000-0003-2184-1338
T +43 1 40400 36590


Prostate; Transcription Factor AP-1; Translational Medical Research

Research group(s)

  • Christian Doppler Laboratory for Applied Metabolomics
    Research Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.
  • MicroOne
    Head: Lukas Kenner
    Research Area: microONE is a research project led by CBmed with a specific focus on the health effects of micro- and nanoplastic particles on human health, which is currently funded as a COMET module by the Austrian Research Promotion Agency (FFG). microONE is a reference project within the “Action Plan Microplastics 2022-2025” of the Federal Ministry for Climate Protection, Environment, Energy, Mobility, Innovation and Technology in Austria (available only in German).
    Head: Lukas Kenner
    Research Area: FANTOM aims to train 10 research fellows by participation in an internationally competitive research programme and address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression.

Research interests

Lukas Kenner is a pathologist and cancer researcher whose research interests center on the molecular mechanisms of cancer initiation, progression, and metastasis. His lab investigates the role of AP-1 and JAK-STAT signaling in cancer development and has developed several gene-targeted mouse models to study new diagnostic approaches and therapies for anaplastic large cell lymphoma (ALCL) and prostate cancer.

In addition to his work on cancer biology, Kenner has also studies the effects of microplastics on colon cancer formation. His research has highlighted the potential adverse health effects of microplastics and has contributed to our understanding of the complex interplay between environmental factors and cancer development. Overall, Kenner's research aims to translate basic science discoveries into clinical applications for cancer patients, with a focus on developing new strategies for cancer prevention and treatment. His work has led to the development of new mouse models for studying cancer, as well as new diagnostic and therapeutic approaches for ALCL and prostate cancer. Additionally, his research on microplastics has contributed to our understanding of the potential health risks associated with environmental factors.

Techniques, methods & infrastructure

Lukas Kenner's research utilizes a range of advanced techniques, methods, and infrastructure to investigate the molecular mechanisms of cancer and develop new diagnostic and therapeutic strategies for cancer patients.

His lab employs tissue microarrays (TMA) of human patient samples, digital pathology, laboratory animal and translational pathology, transgenic mouse modelling, patient-derived grafts (PDX), organoid-derived grafts (ODX), CRISPR-Cas9, RNA knock-down strategies, and whole exome sequencing (WES) to study the biology of cancer cells. Kenner's research also utilizes a variety of molecular pathology methods, including protein, DNA, and RNA analysis, as well as in-vitro cell culture methods. He combines microscopical technology, WES, and PET imaging with clinical data to facilitate diagnostics and treatment of cancer patients using AI. In addition, Kenner's research on the potential health risks of microplastics is supported by cutting-edge detection technology such as Raman Spectroscopy and electron microscopy from human tissue samples. His lab also employs high-end infrastructure for molecular pathology, organoid cell culture, biobanking, and whole-body scan PET for cancer patients. Overall, Kenner's use of advanced techniques and state-of-the-art infrastructure allows for a comprehensive understanding of the complex biology of cancer and the development of new diagnostic and therapeutic strategies for cancer patients.


  • CORE-LAB 2 for Target Identification and Probe Development (TIP) (2016)
    Source of Funding: FFG (Austrian Research Promotion Agency), COMET: K1-Centres
    Principal Investigator
  • PDGFRB function in lymphoma progression (2016)
    Source of Funding: FWF (Austrian Science Fund), Stand alone projects
    Principal Investigator
  • The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (2015)
    Source of Funding: EU, H2020-MSCA-ITN-2015
    Coordinator of the collaborative project
  • Genetic dissection of IL-6 signalling in prostate tumourigenesis (2013)
    Source of Funding: FWF (Austrian Science Fund), Stand alone projects
    Principal Investigator
  • Basic Funding of the LBI Cancer Research (2005)
    Source of Funding: LBG (Ludwig Boltzmann Gesellschaft), LBI
    Principal Investigator

Selected publications

  1. Limberger, T. et al. (2022) ‘KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis’, Molecular Cancer, 21(1). Available at:
  2. Kornauth, C. et al. (2021) ‘Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders’, Cancer Discovery, 12(2), pp. 372–387. Available at:
  3. Liang, H.-C. et al. (2021) ‘Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma’, Nature Communications, 12(1). Available at:
  4. Paolino, M. et al. (2020) ‘RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy’, Nature, 589(7842), pp. 442–447. Available at:
  5. Oberhuber, M. et al. (2020) ‘ <scp>STAT</scp> 3 ‐dependent analysis reveals <scp>PDK</scp> 4 as independent predictor of recurrence in prostate cancer’, Molecular Systems Biology, 16(4). Available at: